Shawn’s Rule‑10b5‑1 Trades: Privia Insider Buys at $2, Sells Near $25—A Bullish Signal or Volatility Cue?

Insider Activity at Privia Health Group: What the Latest Deal Says About the Company’s Outlook

Rule‑10b5‑1 Buying and Selling in One Day On June 26, 2026, director Morris Matthew Shawn executed a Rule 10b5‑1 purchase of 88,110 shares at $2.00, followed by a sale of the same number of shares at a weighted average of $25.33 on June 29. The same trading plan also covered a 63,212‑share buy at $2.00 and a sale at $25.33, all within the same week. The rapid turnaround—from a low‑price buy to a near‑market‑price sell—illustrates how insiders can use pre‑established plans to lock in gains while still complying with SEC rules. For investors, the pattern signals that Shawn is confident in the company’s upward trajectory, yet it also highlights the importance of monitoring Rule 10b5‑1 plans for potential “window‑shifting” effects.

Implications for the Stock’s Momentum The insider buys occurred when Privia’s stock was hovering around $25.55, just above the 52‑week low of $18.77 and near the 52‑week high of $26.51. The sales, executed at $25.33, were only slightly below the prevailing market price, suggesting that the insider was not attempting to unload shares at a discount. Combined with a recent 8.38 % weekly gain and a 20.74 % monthly increase, the insider activity aligns with a broader bullish trend. However, the high trading volume associated with these transactions could temporarily inflate volatility, so traders should be mindful of the short‑term price swings that often accompany insider sales.

What This Means for Investors For long‑term holders, Shawn’s disciplined use of a Rule 10b5‑1 plan is a positive signal of confidence and a hedge against market timing concerns. Yet, the sheer volume of shares traded (over 200,000 in a single week) raises questions about the company’s liquidity and potential dilution from the large option sales recorded in the same period. The 159.69 price‑to‑earnings ratio indicates that the market is valuing the company at a premium, perhaps reflecting optimism around its physician‑enablement platform. Investors should weigh the upside potential against the risk of short‑term price volatility and monitor whether similar insider buying patterns persist.

Profile of Morris Matthew Shawn Shawn’s transaction history is characterized by frequent, small‑block trades under Rule 10b5‑1, with a strong emphasis on buying low and selling at or near market levels. He has consistently purchased shares at $2.00–$3.00 and sold at $24.96–$25.70, generating substantial realized gains each cycle. In addition, he has repeatedly sold large blocks of stock options (often exceeding 3 million shares) under the same plan, indicating a strategic approach to managing both equity and option positions. His pattern of disciplined, rule‑compliant trading suggests a long‑term investment horizon focused on capital appreciation rather than speculation.

Broader Insider Activity Snapshot Beyond Shawn, Privia’s CFO David Mountcastle has also been active, executing multiple buys and sells in the same week as part of a Rule 144 filing. The pattern of regular insider trading across the executive team underscores the company’s intent to maintain a stable capital structure while rewarding employees. For investors, this collective insider activity points to an organization that is proactively managing its equity pool, but also signals that the stock could be susceptible to short‑term price swings when insiders reach their trading windows.

Bottom Line Morris Matthew Shawn’s recent Rule 10b5‑1 trades reinforce a bullish stance on Privia Health Group, aligning with the company’s recent price rally. The disciplined buying and selling strategy offers a level of transparency and confidence for investors, yet the substantial volume of trades and the high option‑sale activity warrant close monitoring. As the company continues to expand its physician platform, insiders’ trading patterns will remain a key indicator of confidence and potential risk for shareholders.